Headache research in 2014: Advancing migraine therapy

The Lancet Neurology

Volumn 14, Issue 1, 2015, Pages 6-7

  Schulte, Laura H ^a   May, Arne ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; MEDICAL RESEARCH; MIGRAINE DISORDERS;

BIOMEDICAL RESEARCH; HUMANS; MIGRAINE DISORDERS;

EID: 84918564335     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70295-9     Document Type: Note

References (12)

1. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014, 83:958-966.
2. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014, 13:1100-1107.
3. Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13:885-892.
4. Walter S, Alibhoy A, Escandon R, Bigal ME Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs 2014, 6:871-878.
5. Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014, 34:968-976.
6. Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 2014, 137:779-794.
7. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009, 132:16-25.
8. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008, 28:226-236.
9. Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012, 166:4-17.
10. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia 2014, 34:853-869.
11. Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med 2014, 6:218ra5.
12. Oktay C, Eken C, Goksu E, Dora B Contribution of verbal suggestion to the therapeutic efficacy of an analgesic agent for acute primary headache. Cephalalgia 2014, published online Oct 10. 10.1177/0333102414553821.